Weiss Ratings Reaffirms Sell (D-) Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Key Points

• Weiss Ratings has reaffirmed a "sell (D-)" rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR), indicating concerns about the stock's performance.
• Despite the negative outlook from Weiss Ratings, other analysts have issued a mix of ratings, with some giving buy ratings and price targets ranging up to $80.00.
• Arrowhead Pharmaceuticals reported a loss of ($1.26) earnings per share for the last quarter, missing expectations, with analysts projecting further losses for the current fiscal year.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities researchers at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Several other analysts have also recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday. Chardan Capital restated a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. Wall Street Zen lowered shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, July 28th. Finally, Royal Bank Of Canada dropped their price target on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $43.14.

Arrowhead Pharmaceuticals Trading Up 1.1%

NASDAQ ARWR traded up $0.40 during trading hours on Wednesday, reaching $36.94. The company had a trading volume of 1,769,409 shares, compared to its average volume of 2,075,464. The stock has a 50-day moving average of $25.37 and a 200 day moving average of $18.50. Arrowhead Pharmaceuticals has a 1-year low of $9.57 and a 1-year high of $39.42. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $5.11 billion, a P/E ratio of -28.86 and a beta of 1.13.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million. During the same quarter in the previous year, the company earned ($1.38) earnings per share. As a group, research analysts anticipate that Arrowhead Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Insider Activity

In other news, insider James C. Hamilton sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the transaction, the insider owned 212,122 shares of the company's stock, valued at $7,424,270. The trade was a 8.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 60,000 shares of company stock worth $1,725,000. Insiders own 4.30% of the company's stock.

Institutional Trading of Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Moody Lynn & Lieberson LLC acquired a new position in Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $213,000. Exchange Traded Concepts LLC raised its position in shares of Arrowhead Pharmaceuticals by 31.8% in the 1st quarter. Exchange Traded Concepts LLC now owns 49,247 shares of the biotechnology company's stock valued at $627,000 after purchasing an additional 11,879 shares in the last quarter. Hsbc Holdings PLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 1st quarter valued at approximately $173,000. GAMMA Investing LLC raised its position in shares of Arrowhead Pharmaceuticals by 297.6% in the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,628 shares in the last quarter. Finally, New York State Teachers Retirement System raised its position in shares of Arrowhead Pharmaceuticals by 6.9% in the 1st quarter. New York State Teachers Retirement System now owns 148,376 shares of the biotechnology company's stock valued at $1,890,000 after purchasing an additional 9,593 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.